Antimicrobial resistance patterns and their encoding genes among Acinetobacter baumannii strains isolated from burned patients

Burns : Journal of the International Society for Burn Injuries
Parisa AsadollahiMohammad Emaneini

Abstract

The purpose of this study was to determine the mechanisms and patterns of antimicrobial resistance among the isolates obtained from burned patients with wound infections at a teaching hospital in Tehran, Iran. A total of 23 Acinetobacter baumannii isolates were collected from patients with burn wound infections between August 2009 and July 2010 from a hospital in Tehran. The susceptibility of these strains against 11 antimicrobial agents was determined by E-test according to the CLSI guidelines. All the resistant strains were then subjected to PCR assay for 28 distinct resistance genes. The most active antimicrobial agent was colistin with 100% sensitivity followed by gentamicin, amikacin and imipenem with 69.5%, 52.1% and 51.1% sensitivity, respectively. The most frequent resistance genes detected were bla(OXA-51-like) genes (n=23; 100%) that was intrinsic to A. baumannii isolates, gyrA (n=23; 100%), carO (n=23; 100%), tetA (n=22; 95.5%), tetB (n=15; 65.2%), intI (n=13; 56.5%) and PER (n=12; 52.1%), respectively. In order to make a proper choice of antibiotic for burn patients, it would be beneficial to physicians to identify drug resistance patterns in A. baumannii isolates.

References

Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·J VilaT Jimenez de Anta
Jan 8, 1999·Journal of Medical Microbiology·R J SewardK J Towner
Apr 4, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G BouJ Martínez-Beltrán
Jul 8, 2005·Journal of Clinical Microbiology·Jane F TurtonTyrone L Pitt
Mar 28, 2006·International Journal of Antimicrobial Agents·Neil WoodfordDavid M Livermore
Aug 19, 2007·BMC Infectious Diseases·Homer C TienAndrew Simor
Nov 13, 2007·Burns : Journal of the International Society for Burn Injuries·Harvey ChimColin Song
Dec 21, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K J TownerUNKNOWN ARPAC Steering Group
Dec 19, 2008·International Journal of Antimicrobial Agents·Kyungwon LeeUNKNOWN KONSAR Group
Apr 14, 2009·Diagnostic Microbiology and Infectious Disease·Young Kyoung ParkKwan Soo Ko
Jun 18, 2009·Annals of Clinical Microbiology and Antimicrobials·Vijaya B SrinivasanWondwossen A Gebreyes
Sep 18, 2009·Journal of Infection in Developing Countries·Raffaele ZarrilliAthanassios Tsakris
Oct 28, 2009·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Anna PapaEfimia Souliou
Jan 19, 2010·Burns : Journal of the International Society for Burn Injuries·Edward F KeenClinton K Murray
Feb 4, 2010·American Journal of Infection Control·Karina Eugênia Schimith BierLibera Maria Dalla Costa
Jul 9, 2010·BMC Infectious Diseases·Lemuel L DentRobert B Hulette
Sep 28, 2010·American Journal of Infection Control·Marcelo CarneiroAfonso L Barth

❮ Previous
Next ❯

Citations

Jul 17, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Abbas BahadorFarhad B Hashemi
Sep 26, 2014·Annals of Clinical Microbiology and Antimicrobials·Mohtaram NasrolaheiDavoud Esmaeili
Dec 17, 2014·Journal of Burn Care & Research : Official Publication of the American Burn Association·Andrew LindfordJyrki Vuola
Jan 22, 2015·Burns : Journal of the International Society for Burn Injuries·Himen SalimizandSaeid Jamehdar Amel
Jun 4, 2013·Burns : Journal of the International Society for Burn Injuries·Omid PajandZoya Hojabri
May 6, 2015·Osong Public Health and Research Perspectives·Jale MoradiAbbas Bahador
Jan 14, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hadi Razavi NikooJalal Mardaneh
Mar 31, 2015·International Journal of Immunopathology and Pharmacology·Abdolaziz Rastegar LariMorovat Taherikalani
Apr 22, 2016·The Open Microbiology Journal·Maryam PourhajibagherAbbas Bahador
Mar 8, 2017·Journal of the Chinese Medical Association : JCMA·Saeed ShojaNasim Ebrahimifard
Nov 19, 2020·Revista Do Instituto De Medicina Tropical De São Paulo·Maryam BeheshtiVeeranoot Nissapatorn
May 8, 2019·Journal of Global Antimicrobial Resistance·Fatemeh JavanmardiAbdolkhalegh Keshavarzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.